Drug Trial Radar · NCT05221658
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC
Last checked: Nov 19, 2026Latest source record: Aug 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
60
Planned (sponsor's estimate)
Start
Aug 25, 2022
Primary completion
Jun 30, 2024
Study completion Aug 30, 2025
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Feb 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is conducted in patients with Locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma (ESCC) or esophageal adenosquamous carcinoma. This study includes three arms: A, B1, and B2. Arm A will receive HLX07 combination therapy with HLX10 and Chemotherapy (Cisplatin+5-FU) as first line treatment. Arm B (Patients with EGFR expression H score ≥ 200) and Arm C (Patients with EGFR expression H score \< 200) will receive HLX07 monotherapy as third-line or above treatment. All of eligible patients will receive study drug treatment until loss of clinical benefit, unacceptable toxicity, death, withdrawal of informed consent (whichever occurs first, HLX10 treatment up to 2 years).
Conditions
- ESCC or Esophageal Adenosquamous Carcinoma
Interventions
HLX07+HLX10+ Cisplatin+5-FUDrug
HLX07 1000mg + HLX10 200mg + Cisplatin 50 mg/m2 + 5-FU 2400mg/m2
HLX07Drug
HLX07 1000mg iv Q2w
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: up to 2 years
- PFSTime frame: from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 2 years
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academic of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Not yet recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China · Not yet recruiting
Cancer Hospital Chinese Academic of Medical Sciences, Shenzhen Center
Shenzhen, Guangdong, China · Not yet recruiting
Anyang Cancer Hospital
Anyang, Hebei, China · Not yet recruiting
Xingtai People's Hospital
Xingtai, Hebei, China · Not yet recruiting
Henan Cancer Hospital & Affiliated Cancer Hospital of Zhengzhou University
Zhenzhou, Henan, China · Not yet recruiting
Hunan Cancer Hospitla
Changsha, Hunan, China · Not yet recruiting
Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital
Nanjing, Jiangsu, China · Not yet recruiting
Jiangsu People Hospital & The First Affiliated with Nanjing Medical University
Nanjing, Jiangsu, China · Not yet recruiting
Xuzhou Center Hospital
Xuzhou, Jiangsu, China · Not yet recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Not yet recruiting
Affiliated Hospital of Jining Medical University
Jining, Shandong, China · Not yet recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Not yet recruiting
Shanxi Cancer Hospital
Taiyuan, Shanxi, China · Not yet recruiting
Sichuan Cancer Hospital
Chengdu, Sichuan, China · Not yet recruiting
Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center
Kunming, Yunnan, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.